The FDA had stamped an approval on Pfizer's ($PFE) new kidney cancer drug axitinib, which the drug giant plans to market...
After being rejected twice by regulatory officials, Amylin has finally won FDA approval to sell Bydureon, its once-weekly...
Biogen Idec's ($BIIB) lead dealmaker, Steve Holtzman, recently sat down with Xconomy's Luke Timmerman to outline just why...
Trends usually take at least a few months to get started. In biotech's case, they can seem to brew up like a squall and pass...
Other major pharma chiefs don't see the same opportunity in acquiring Illumina ($ILMN) as does Roche CEO Severin Schwan,...
With the rare disease drug field as crowded as ever, BioMarin Pharmaceutical ($BMRN) is in the market to snap up smaller...
Infinity Pharmaceuticals' ($INFI) lead therapy failed a critical mid-stage hurdle as investigators moved to shut down a study...
Christoph Westphal's Verastem, a preclinical-stage biotech focused on cancer stem cell research, seemingly defied gravity...
Xconomy has the story this morning about a new biotech being launched in Seattle under the guidance of a pair of noted biotech...
A day after Roche's ($RHHBY) hostile $5.7 billion bid to scoop up Illumina ($ILMN) hit the news, investors are wagering that...
